MX2022014943A - Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna. - Google Patents
Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna.Info
- Publication number
- MX2022014943A MX2022014943A MX2022014943A MX2022014943A MX2022014943A MX 2022014943 A MX2022014943 A MX 2022014943A MX 2022014943 A MX2022014943 A MX 2022014943A MX 2022014943 A MX2022014943 A MX 2022014943A MX 2022014943 A MX2022014943 A MX 2022014943A
- Authority
- MX
- Mexico
- Prior art keywords
- cov
- sars
- epitopes
- inventors
- polypeptides
- Prior art date
Links
- 241001678559 COVID-19 virus Species 0.000 title abstract 7
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 229940022962 COVID-19 vaccine Drugs 0.000 abstract 1
- 241000315672 SARS coronavirus Species 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 230000005182 global health Effects 0.000 abstract 1
- 238000000126 in silico method Methods 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 229940125575 vaccine candidate Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Abstract
La pandemia del coronavirus 2 causante del síndrome respiratorio agudo severo (SARS-CoV-2) ha surgido innegablemente como la amenaza para la salud global más grande para la humanidad en este siglo; las vacunas de SARS-CoV-2 serán esenciales para reducir la morbilidad y mortalidad si el virus se establece por sí mismo en la población; los inventores han establecido vacunas candidatas contra el SARS-CoV-2; en particular, los inventores han identificado epítopes específicos que se incluirán en los candidatos de vacuna gracias al análisis in silico de la secuencia de aminoácidos de estas proteínas para mapear los epítopes del MHC-I y-II predichos por el software en línea (NetMHC-4.0 y NetMHCII-2.3) y el software de predicción de la unión al péptido; epítopes de células B fueron mapeados también usando el software en línea (BepiPred-2.0 y Discotope), así como regiones ricas en epítopes cuyas secuencias son homólogas entre los SARS-CoV-2 y-CoV-1; finalmente, los inventores han generado algunos anticuerpos de CD40 específicos que comprenden uno o más polipéptidos de SARS-CoV-2 de la presente invención y que son adecuados para propósitos de vacuna; por lo tanto, la presente invención se refiere a polipéptidos de SARS-CoV-2 y usos de los mismos para propósitos de vacuna.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20305550 | 2020-05-26 | ||
EP20306415 | 2020-11-20 | ||
EP21305092 | 2021-01-26 | ||
EP21305482 | 2021-04-12 | ||
PCT/EP2021/064098 WO2021239838A2 (en) | 2020-05-26 | 2021-05-26 | Severe acute respiratory syndrome coronavirus 2 (sars-cov-2) polypeptides and uses thereof for vaccine purposes |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022014943A true MX2022014943A (es) | 2023-03-08 |
Family
ID=76159441
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022014943A MX2022014943A (es) | 2020-05-26 | 2021-05-26 | Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna. |
Country Status (9)
Country | Link |
---|---|
US (1) | US20230212231A1 (es) |
EP (1) | EP4157343A2 (es) |
JP (1) | JP2023528017A (es) |
KR (1) | KR20230042222A (es) |
BR (1) | BR112022024063A2 (es) |
CA (1) | CA3184802A1 (es) |
CO (1) | CO2022018389A2 (es) |
MX (1) | MX2022014943A (es) |
WO (1) | WO2021239838A2 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20240066114A1 (en) * | 2020-08-31 | 2024-02-29 | CureVac SE | Multivalent nucleic acid based coronavirus vaccines |
WO2023088968A1 (en) * | 2021-11-17 | 2023-05-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Universal sarbecovirus vaccines |
CN114807179B (zh) * | 2022-06-01 | 2022-10-21 | 广州达博生物制品有限公司 | 一种新型冠状病毒肺炎疫苗的构建与应用 |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US5219740A (en) | 1987-02-13 | 1993-06-15 | Fred Hutchinson Cancer Research Center | Retroviral gene transfer into diploid fibroblasts for gene therapy |
EP0428534B1 (en) | 1988-06-14 | 1995-03-29 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US5399346A (en) | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
AU8200191A (en) | 1990-07-09 | 1992-02-04 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | High efficiency packaging of mutant adeno-associated virus using amber suppressions |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
ES2197145T3 (es) | 1991-08-20 | 2004-01-01 | The Government Of The Usa As Represented By The Secretary Of The Deptm. Of Health And Human Services | Transferencia de genes mediada por adenovirus al gastrointestinal. |
CN1487996B (zh) | 2000-11-30 | 2010-06-16 | 米德列斯公司 | 用于生产人类抗体的转基因转染色体啮齿动物 |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
CN101899114A (zh) | 2002-12-23 | 2010-12-01 | 惠氏公司 | 抗pd-1抗体及其用途 |
CN100588430C (zh) * | 2004-02-20 | 2010-02-10 | 复旦大学 | 基于表位的SARS-Cov基因疫苗及其构建 |
PL2439273T3 (pl) | 2005-05-09 | 2019-08-30 | Ono Pharmaceutical Co., Ltd. | Ludzkie przeciwciała monoklonalne przeciwko białku programowanej śmierci komórki 1(pd-1) oraz metody leczenia nowotworów z wykorzystaniem przeciwciał anty-pd-1 samodzielnie lub w połączeniu z innymi immunoterapeutykami |
RS54271B1 (en) | 2005-07-01 | 2016-02-29 | E. R. Squibb & Sons, L.L.C. | HUMAN MONOCLONIC ANTIBODIES FOR LIGAND PROGRAMMED DEATH 1 (PD-L1) |
KR20090114425A (ko) | 2007-02-02 | 2009-11-03 | 베일러 리서치 인스티튜트 | 표적화 사람화된 모노클로날 항체와 복합체화된 다가변성 항원 |
HUE034465T2 (en) | 2008-02-11 | 2018-02-28 | Cure Tech Ltd | Monoclonal antibodies for tumor treatment |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
WO2010009346A2 (en) | 2008-07-16 | 2010-01-21 | Baylor Research Institute | Hiv vaccine based on targeting maximized gag and nef to dendritic cells |
KR20110074850A (ko) | 2008-08-25 | 2011-07-04 | 앰플리뮨, 인크. | Pd-1 길항제 및 그의 사용 방법 |
MX2011002252A (es) | 2008-08-25 | 2011-06-24 | Amplimmune Inc | Composiciones de antagonistas del pd-1 y metodos de uso. |
CN114835812A (zh) | 2008-12-09 | 2022-08-02 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
DK2406289T3 (en) | 2009-03-10 | 2017-05-01 | Baylor Res Inst | ANTIGEN PRESENTING CELL TARGETED ANTIVIRUS VACCINES |
US8289808B2 (en) | 2009-04-16 | 2012-10-16 | Chevron U.S.A., Inc. | System and method to estimate compressional to shear velocity (VP/VS) ratio in a region remote from a borehole |
MX2012003058A (es) | 2009-09-14 | 2012-05-22 | Baylor Res Inst | Vacunas dirigidas a celulas de langerhans. |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
LT3279215T (lt) | 2009-11-24 | 2020-04-10 | Medimmune Limited | Tiksliniai surišantys agentai prieš b7-h1 |
KR20130108295A (ko) | 2010-08-13 | 2013-10-02 | 베일러 리서치 인스티튜트 | 항원-제시 세포에 항체에 대한 보조제를 직접 표적화함을 기초로 하는 신규 백신 보조제 |
WO2012059882A2 (en) | 2010-11-05 | 2012-05-10 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
CN103987405B (zh) | 2011-11-28 | 2017-03-29 | 默克专利股份公司 | 抗pd‑l1抗体及其用途 |
WO2014085580A1 (en) * | 2012-11-28 | 2014-06-05 | Baylor Research Institute | Methods and compositions involving a flu vaccine |
AU2014316682B2 (en) | 2013-09-06 | 2018-11-22 | Aurigene Discovery Technologies Limited | 1,2,4-oxadiazole derivatives as immunomodulators |
SI3041828T1 (sl) | 2013-09-06 | 2018-10-30 | Aurigene Discovery Technologies Limited | 1,3,4-oksadiazolni in 1,3,4-tiadiazolni derivati kot imunomodulatorji |
US10849972B2 (en) * | 2018-11-27 | 2020-12-01 | King Adulaziz University | Trimeric S1-CD40L fusion protein vaccine against Middle East respiratory syndrome-coronavirus |
-
2021
- 2021-05-26 CA CA3184802A patent/CA3184802A1/en active Pending
- 2021-05-26 KR KR1020227045248A patent/KR20230042222A/ko unknown
- 2021-05-26 MX MX2022014943A patent/MX2022014943A/es unknown
- 2021-05-26 WO PCT/EP2021/064098 patent/WO2021239838A2/en active Application Filing
- 2021-05-26 BR BR112022024063A patent/BR112022024063A2/pt unknown
- 2021-05-26 EP EP21728243.3A patent/EP4157343A2/en active Pending
- 2021-05-26 JP JP2022573138A patent/JP2023528017A/ja active Pending
- 2021-05-26 US US17/927,804 patent/US20230212231A1/en active Pending
-
2022
- 2022-12-19 CO CONC2022/0018389A patent/CO2022018389A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230212231A1 (en) | 2023-07-06 |
BR112022024063A2 (pt) | 2023-01-31 |
JP2023528017A (ja) | 2023-07-03 |
EP4157343A2 (en) | 2023-04-05 |
WO2021239838A3 (en) | 2022-03-17 |
WO2021239838A2 (en) | 2021-12-02 |
CO2022018389A2 (es) | 2023-02-06 |
CA3184802A1 (en) | 2021-12-02 |
KR20230042222A (ko) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022014943A (es) | Polipéptidos de coronavirus 2 causante del síndrome respiratorio agudo severo (sars-cov-2) y usos de los mismos para propositos de vacuna. | |
MX2021011687A (es) | Composiciones inmunogenicas y vacunas que comprenden peptidos y proteinas del virus de la peste porcina africana y usos de las mismas. | |
RU2020132040A (ru) | Общие неоантигены | |
EA201790976A1 (ru) | Терапевтические вакцины против hpv16 | |
EA202091710A1 (ru) | Антитела против cd73 и способы их применения | |
UA124343C2 (uk) | Капсиди аденоасоційованого вірусу і спосіб його використання | |
EA201791148A1 (ru) | Способ определения абсолютных количеств hla-рестриктированных раковых пептидов, образовавшихся в результате естественного процессинга | |
EA202091335A1 (ru) | Ограниченные hla класса i t-клеточные рецепторы против мутантного ras | |
MX2016015383A (es) | Receptores de celulas t anti - papilomavirus 16 e7 humano. | |
Müller et al. | Human coronavirus NL63 open reading frame 3 encodes a virion-incorporated N-glycosylated membrane protein | |
EA201691111A1 (ru) | Химерные белки фактора viii и их применение | |
EA200901060A1 (ru) | Новый способ и композиции | |
JP2015212284A5 (es) | ||
BR112014030797A2 (pt) | epítopo de peptídeo isolado, proteína recombinante, molécula de ácido nucléico isolada, vetor, célula hospedeira, método para preparar o epítopo de peptídeo ou mutante do mesmo, vacina de proteína, uso do epítopo de peptídeo ou mutante do mesmo, vacina de gene, uso da molécula de ácido nucléico, composição farmacêutica, anticorpo monoclonal e um fragmento de ligação ao antígeno do mesmo, linha de célula de hibridoma, kit, método para detecção da presença ou nível da proteína hbsag em uma amostra e uso do anticorpo monoclonal ou fragmento de ligação ao antígeno do mesmo | |
EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
BR112014018884A2 (pt) | antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b | |
EA201100071A1 (ru) | Новые композиции и способы | |
CO2017011431A2 (es) | Proteínas de fusión de receptor de factor de crecimiento epidermal variante iii - mesotelina | |
CL2017000200A1 (es) | Célula huésped mejorada para producir proteinas | |
MX2019002178A (es) | Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74). | |
MX2019003156A (es) | Combinaciones de vacunas novedosas contra el virus del zika y construcciones de anticuerpos de adn para usar contra el virus del zika. | |
Chattopadhyay et al. | Development and characterization of monoclonal antibody against non-structural protein-2 of Chikungunya virus and its application | |
Aparicio et al. | Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses | |
EA201890187A1 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
AR051853A1 (es) | Vacuna para aumentar el crecimiento basada en epitopes neutralizantes |